Propanc Biopharma, Inc. (PPCB) stock forecast & analysis
1.75
NasdaqCM · USD
Down: -0.48, -21.5%
1 analysis
- Open
- 1.93
- Previous close
- 2.23
- Day range
- 1.65 – 1.94
- 52-week range
- 0.9500 – 81.00
- Volume (shares)
- 2.19M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 2.28M
- P/E ratio
- 0.00
- Dividend yield
- Not available
- Beta
- 3.27
- Market cap
- 3.99M
Market Scanner’s AI analysis of Propanc Biopharma, Inc. (PPCB), updated August 2026: PPCB's pancreatic cancer therapy PRP shows strong preclinical data, driving significant short-term stock gains.
Summary
PPCB's pancreatic cancer therapy PRP shows strong preclinical data, driving significant short-term stock gains.
Recent analyses for PPCB covered positive preclinical data for its pancreatic cancer therapy, PRP, which demonstrated significant tumor growth inhibition and survival benefits. This news coincided with a substantial increase in the stock price, with notable short-term and medium-term upward momentum. However, the long-term trend remains bearish, and technical indicators suggest the stock may be overextended in the short term.
PPCB news & sentiment
News sentiment was overwhelmingly positive, driven by strong preclinical data for PPCB's pancreatic cancer therapy and a completed share repurchase program. Social media discussion reflected this positive news, with significant upward momentum observed in stock price discussions.
PPCB technical picture
The stock exhibited strong upward momentum with significant gains over 7-, 30-, and 91-day periods. Price action was notably above short- and medium-term moving averages, though below the long-term average. Momentum indicators suggested extreme buying pressure and potential short-term overextension.
Fundamentals
PPCB reported net losses from 2022 to 2025, with a significant increase in the net loss for fiscal year 2025. Cash flow from operations has been negative for the past four fiscal years. The company has total debt exceeding its total cash, though its current ratio suggests adequate short-term liquidity.
Factors discussed — upside
- Strong recent upward momentum in stock price (+102.7% 7-day change, +84.3% 30-day change)
- Price trading significantly above 10-day EMA and 50-day SMA
- Compelling preclinical data for pancreatic cancer therapy PRP showing >90% tumor growth inhibition and survival benefit
- Positive news flow regarding PRP's potential against RAS-driven cancers and clearance for Phase 1b study
- Completion of the first tranche of a $5.0 million share repurchase program
Factors discussed — risks
- Long-term trend remains bearish, with price 64.2% below 200-day SMA
- RSI at 76.21, indicating potential short-term overextension
- MFI at 99.89, indicating extreme buying pressure
- Consistent net losses reported annually from 2022 to 2025, with a significant increase in FY2025
- Negative cash flow from operations for the past four fiscal years
- Therapeutic advancements
- Market momentum
- Financial health
- Technical indicators
Summary updated .
PPCB technical indicators
Common technical indicators for PPCB, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.39 | Price above |
| 10-day exponential moving average | 1.41 | Price above |
| Relative strength index (14-day) | 60.02 | Neutral |
| MACD line (12/26/9) | 0.0486 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.69 – 1.78 | Price inside the bands |
Analyses
Recent PPCB.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Propanc Biopharma, Inc.?
- The bull case for PPCB centers on compelling preclinical data for its pancreatic cancer therapy, PRP, which has shown significant tumor growth inhibition and survival benefits. This positive news, alongside potential against RAS-driven cancers and clearance for a Phase 1b study, has driven strong recent stock price momentum and completed share repurchase program tranches.
- What are the risks for Propanc Biopharma, Inc.?
- Risks for PPCB include a long-term bearish stock trend and technical indicators suggesting the stock may be overextended following recent gains. The company has also reported consistent net losses and negative cash flow from operations over the past several years.
- Is Propanc Biopharma, Inc. bullish or bearish?
- Recent AI analyses of Propanc Biopharma, Inc. examined factors on both sides. Discussed upside: The bull case for PPCB centers on compelling preclinical data for its pancreatic cancer therapy, PRP, which has shown significant tumor growth inhibition and survival benefits. This positive news, alongside potential against RAS-driven cancers and clearance for a Phase 1b study, has driven strong recent stock price momentum and completed share repurchase program tranches. Discussed risks: Risks for PPCB include a long-term bearish stock trend and technical indicators suggesting the stock may be overextended following recent gains. The company has also reported consistent net losses and negative cash flow from operations over the past several years. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Propanc Biopharma, Inc.?
- News sentiment was overwhelmingly positive, driven by strong preclinical data for PPCB's pancreatic cancer therapy and a completed share repurchase program. Social media discussion reflected this positive news, with significant upward momentum observed in stock price discussions.
- Bundles used
- gemini-low-v2
Run a fresh PPCB.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every PPCB.US report already in the library